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Introduction
Roche and Genentech both developed their first
platform cell culture process using chemically-defined
media independently. This resulted in significantly dif-
ferent processes with regards to operations and media
formulations. The decision was made to evaluate both
and decide for one existing platform. Drivers and ben-
efits of a single upstream cell culture platform were
the maximization of flexibility with regard to process
development, clinical and commercial manufacturing
by execution of any process at any network facility
with standard transfer effort and by minimization of
component lists and raw material inventories across
sites. Furthermore capturing benefits of improvements
made by all sites funneled into a common knowledge
base benefits the whole organization. And process
characterization and validation data could be leveraged
across the entire organization what means less
resource expenditure for PC/PV.
The existing independent platforms were evaluated if
there is a clear benefit in going forward with a given
platform or certain aspects of a platform. The compari-
son consisted in a technical (cell culture performance,
product quality, manufacturability) and a business case
evaluation (product titer, timelines to launch, costs, IP.
In result both platforms are capable of achieving suffi-
cient titers for platform process (2-4 g/L) with accepta-
ble product quality. There existed no major business
driver to select one process over the other.
Development
For development of new basal and feed media knowl-
edge from two legacy efforts was leveraged and so
potential synergies and performance benefits could be
achieved (Figure 1). Based on platform evaluation
results, decision was made to harmonize existent CHO
host cell line, seed train medium and feeding strategy
(chosen from the two existing platforms).
Results
The cell culture media and feed optimization strategy
started with a paper exercise to compare existing in-
house chemically defined media formulations and iden-
tify components/component groups for further evalua-
tion. Subsequently identified conditions were screened
in high-throughput cell culture systems (HTS-CC) to
identify beneficial components and remove components
that are not required. Optimized best cases were con-
firmed in 2L bioreactors with 6 model cell lines and the
final process was up-scaled to pilot scale.
Promising results from HTS-CC media screening were
confirmed in a 2L-bioreactor experiment. The new plat-
form medium and feed were finalized after a series of
2L optimization experiments. The process was success-
ful up-scaled to 250L single-use bioreactor (SUB) and
400L stainless steel bioreactor with two model cell lines.
Growth and titer were comparable to 2L satellites.
In the course of the platform implementation four
new GMP raw materials (dry powders and stock solu-
tion) were developed and tested. Raw material shelf life
stability retesting and extension were initiated. Global
specifications were established for equipment and site
independent platform application and the applicability
for global production units is given.
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High temperature/short time treatment (HTST) com-
patibility was tested. The sterile hold for liquid media
was initiated.
Summary
New chemically defined platform media (basal and feed)
were developed by leveraging data and knowledge from
the two Genentech and Roche legacy platform pro-
cesses, and through a series of experiments including
high-throughput systems for cell culture, shake flasks,
2L bioreactors and pilot-scale bioreactors. An average
increase in final titer of 30% was achieved compared to
the two legacy platforms.
The final process resulted in product quality attributes
(glycans, charge variants, size) that were comparable to
historical data. No new variants were detected. The final
and fully harmonized platform process is specified and
implemented.
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Figure 1 Schematic diagram of major elements of the two legacy platforms and the optimization of medium and feed respective the
leveraging of knowledge from two existing legacy platforms.
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